Amendment of a drug utilization study protocol based on results from a real-world pilot study of liraglutide use in Europe

Economic and time constraints may incite researchers to avoid formalized pilot studies. Here, we report results of a pilot study that amended the ensuing drug utilization study (DUS) protocol, thus ascertaining fit-for-purpose data availability and quality, to better support regulatory decision-making. This retrospective, multicenter medical chart review in Germany and Italy, 6 months after Saxenda® (liraglutide 3.0 mg, a once-daily human glucagon-like peptide-1 analog for weight management) launch, ahead of a full DUS, collected patient data. The target study population included 100 initiators (25 Saxenda® and 25 Victoza® initiators in both Germany and Italy). Written informed consent was obtained before medical chart data extraction. Overall, 218 sites were contacted, with 39 Saxenda® initiators (33 in Italy; six in Germany) and 52 Victoza® initiators (31 in Italy; 21 in Germany). Patient records were obtained for all enrolled Saxenda® and Victoza® initiators in Italy and Germany; however, availability of individual study variables varied, with follow-up body weight showing the greatest degree of missingness among Saxenda® initiators. The pilot study indicated a poor enrollment feasibility of Saxenda® initiators in Germany and an unfit-for-purpose dose-related data quality. Based on these findings, refinements were implemented in the ensuing DUS protocol to improve the collection of fit-for-purpose real-world data for regulatory decision-making.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-18
DOI
https://doi.org/10.1038/s41598-026-79385-2
Citations
1
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Amendment of a drug utilization study protocol based on results from a real-world pilot study of liraglutide use in Europe

Jens Aberle, Naveen Rathor, Paolo Sbraccia, Atheline Major‐Pedersen et al.
1 citations
Scientific Reports
Pharmacology and Obesity Treatment
article

Amendment of a drug utilization study protocol based on results from a real-world pilot study of liraglutide use in Europe

Jens Aberle, Naveen Rathor, Paolo Sbraccia, Atheline Major‐Pedersen, Anne Helene Olsen
article en
1 citations

Abstract

Economic and time constraints may incite researchers to avoid formalized pilot studies. Here, we report results of a pilot study that amended the ensuing drug utilization study (DUS) protocol, thus ascertaining fit-for-purpose data availability and quality, to better support regulatory decision-making. This retrospective, multicenter medical chart review in Germany and Italy, 6 months after Saxenda® (liraglutide 3.0 mg, a once-daily human glucagon-like peptide-1 analog for weight management) launch, ahead of a full DUS, collected patient data. The target study population included 100 initiators (25 Saxenda® and 25 Victoza® initiators in both Germany and Italy). Written informed consent was obtained before medical chart data extraction. Overall, 218 sites were contacted, with 39 Saxenda® initiators (33 in Italy; six in Germany) and 52 Victoza® initiators (31 in Italy; 21 in Germany). Patient records were obtained for all enrolled Saxenda® and Victoza® initiators in Italy and Germany; however, availability of individual study variables varied, with follow-up body weight showing the greatest degree of missingness among Saxenda® initiators. The pilot study indicated a poor enrollment feasibility of Saxenda® initiators in Germany and an unfit-for-purpose dose-related data quality. Based on these findings, refinements were implemented in the ensuing DUS protocol to improve the collection of fit-for-purpose real-world data for regulatory decision-making.

Scientific Reports
University of Rome Tor Vergata (IT), Universität Hamburg (DE), Novo Nordisk (Denmark) (DK)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon